帕洛诺司琼VS昂丹司琼.pdf

Annals of Oncology 14: 1570–1577, 2003
Original article DOI:
Palonosetron improves prevention of chemotherapy-induced
nausea and vomiting following moderately emetogenic
chemotherapy: results of a double-blind randomized phase III trial
comparing single doses of palonosetron with ondansetron
R. Gralla1, M. Lichinitser2, S. Van der Vegt3, H. Sleeboom4, J. Mezger5, C. Peschel6, G. Tonini7,
R. Labianca8, A. Macciocchi9 & M. Aapro10*
1New York Lung Cancer Alliance, New York, NY, USA; 2Cancer Research Center, Moscow, Russia; 3Ziekenhuis Ondenrijn, Van Heuven Goedhartlaan, Utrecht;
4Ziekenhuis Leyenburg, Den Haag, The Netherlands; 5St Vincentius-Kliniken, Karlsruhe; 6Klinikum rechts der Isar der Technischen Universität München, Munich,
Germany; 7Oncology Department Campus, Bio-Medico University, Rome; 8Ospedali Riuniti di Bergamo, Unitá Operativa di Oncologia Medica, Bergamo, Italy;
9Helsinn Healthcare SA, Lugano; 10IMO, Clinique de Genolier, Genolier, Vaud, Switzerland
Received 10 June 2003; revised 17 July 2003; accepted 21 July 2003
Background: Although all first-generation 5-HT3 receptor antagonists demonstrate efficacy in preventing
acute chemotherapy-induced nausea and vomiting (CINV), effective prevention of d